Evidence map›Paper›PMID 39183206›Full record

Observational studyImmunogenetics2024

The effect of circulating cytokines on the risk of systemic lupus erythematosus: Mendelian randomization and observational study.

Dan Xue, Yu Qian, Xiao Tu, Mu He, Fengling Xing, Yunqing Ren, Chengda Yuan

Abstract readObservational Study
In one paragraph

Observational study in Immunogenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dan XueDermatology Department, Hangzhou TCM Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Yu QianInstitute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China.
Xiao TuNephrology Department, Hangzhou TCM Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Mu HeDermatology Department, Hangzhou TCM Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Fengling XingDermatology Department, Hangzhou TCM Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Yunqing RenDepartment of Dermatology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Chengda YuanDermatology Department, Hangzhou TCM Hospital, Zhejiang Chinese Medical University, Hangzhou, China. hztcmycd11@163.com.ORCID 0000-0002-0734-1233

Funding

the Construction Fund of Medical Key Disciplines of Hangzhou 2020SJZDXK03
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder, the etiology of which involves the alterations in circulating cytokine levels. However, the cause-and-effect relationships and in-depth clinical relevance of them remain to be systematically investigated. We conducted a two-sample Mendelian randomization (MR) study to assess the causality of circulating cytokine levels and SLE and found that genetically determined elevated CTACK and IL-18 were associated with an increased risk of SLE, whereas a higher level of GRO-a was associated with decreased risk. Furthermore, we performed an observational study to further reveal the association between 27 cytokines and the severity measured by SLEDAI score, as well as lupus nephritis (LN), of SLE. We identified six cytokines (MCP1, MIP1β, CTACK, IP10, HGF, IL18, IL13) that were identified as associated with the clinical severity of SLE, and five cytokines, especially IL18, were related with LN and may have good diagnostic value. Moreover, we also predicted four compounds that might have good binding activities with IL18. The evidence supported a potential causal role of circulating cytokines on the risk of SLE. Targeting IL18 might be a meaningful strategy for the prevention or treatment of SLE, especially in LN patients.

Indexed as

CytokinesLupus Erythematosus, SystemicMendelian Randomization AnalysisGenetic Predisposition to DiseaseHumansInterleukin-18Lupus NephritisPolymorphism, Single NucleotideRisk FactorsCytokinesIL18 protein, humanInterleukin-18CytokineMendelian randomizationObservational studySystemic lupus erythematosus

Identifiers

PMID39183206
PMCPMC11496328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.